Donepezil hydrochloride + Placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Attention Impairment

Conditions

Attention Impairment

Trial Timeline

Jul 2, 2008 โ†’ May 26, 2009

About Donepezil hydrochloride + Placebo

Donepezil hydrochloride + Placebo is a phase 3 stage product being developed by Eisai for Attention Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT00688376. Target conditions include Attention Impairment.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00688376Phase 3Completed
NCT00293176ApprovedCompleted

Competing Products

20 competing products in Attention Impairment

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
85
Atomoxetine + PlaceboEli LillyPhase 2/3
65
AtomoxetineEli LillyApproved
85
Atomoxetine HydrochlorideEli LillyApproved
85
AtomoxetineEli LillyPhase 3
77
AtomoxetineEli LillyApproved
85
Atomoxetine hydrochloride + PlaceboEli LillyApproved
85
CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3
77
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)Eli LillyPhase 2/3
65
Atomoxetine + PlaceboEli LillyApproved
85
AtomoxetineEli LillyApproved
85
AtomoxetineEli LillyPre-clinical
23
Atomoxetine HydrochlorideEli LillyApproved
85
Atomoxetine hydrochlorideEli LillyPhase 3
77
Atomoxetine Hydrochloride + PlaceboEli LillyApproved
85
atomoxetineEli LillyPhase 3
77
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/dayEli LillyPhase 3
77
Atomoxetine HydrochlorideEli LillyApproved
85
Atomoxetine HydrochlorideEli LillyPhase 3
77
Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + PlaceboEli LillyPhase 3
77